TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Nature

Volumn 554, Issue 7693, 2018, Pages 544-548

  Mariathasan, Sanjeev ^a   Turley, Shannon J ^a   Nickles, Dorothee ^a   Castiglioni, Alessandra ^a   Yuen, Kobe ^a   Wang, Yulei ^a   Kadel, Edward E ^a   Koeppen, Hartmut ^a   Astarita, Jillian L ^a   Cubas, Rafael ^a   Jhunjhunwala, Suchit ^a   Banchereau, Romain ^a   Yang, Yagai ^a   Guan, Yinghui ^a   Chalouni, Cecile ^a   Ziai, James ^a   Şenbabaoǧlu, Yasin ^a   Santoro, Stephen ^a   Sheinson, Daniel ^a   Hung, Jeffrey ^a   Giltnane, Jennifer M ^a   Pierce, Andrew A ^a   Mesh, Kathryn ^a   Lianoglou, Steve ^a   Riegler, Johannes ^a   Carano, Richard A D ^a   Eriksson, Pontus ^b   Höglund, Mattias ^b   Somarriba, Loan ^c   Halligan, Daniel L ^c   Van Der Heijden, Michiel S ^d   Loriot, Yohann ^e   Rosenberg, Jonathan E ^f   Fong, Lawrence ^g   Mellman, Ira ^a   Chen, Daniel S ^a   Green, Marjorie ^a   Derleth, Christina ^a   Fine, Gregg D ^a   Hegde, Priti S ^a   Bourgon, Richard ^a   Powles, Thomas ^h   more..

^a GENENTECH INC   (United States)

^b LUND UNIVERSITY   (Sweden)

^c Fios Genomics Ltd   (United Kingdom)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; GAMMA INTERFERON RECEPTOR 1; PROGRAMMED DEATH 1 LIGAND 1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1; ANTIBODY; CD274 PROTEIN, HUMAN; COLLAGEN; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ACVR1 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CD8+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CLINICAL OUTCOME; COHORT ANALYSIS; COLON CARCINOMA; CONTROLLED STUDY; DRUG RESPONSE; EFFECTOR CELL; FEMALE; FIBROBLAST; GENE; HUMAN; HUMAN TISSUE; IFNGR1 GENE; MOUSE; MOUSE MODEL; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RNA SEQUENCE; SIGNAL TRANSDUCTION; STROMA CELL; TGFB1 GENE; TGFBR2 GENE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR VOLUME; UROGENITAL TRACT CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; CYTOLOGY; DISEASE MODEL; DRUG EFFECT; DRUG RESISTANCE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METASTASIS; MUTATION; PATHOLOGY; PHENOTYPE; TREATMENT OUTCOME; URINARY TRACT TUMOR; UROTHELIUM;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; B7-H1 ANTIGEN; CD8-POSITIVE T-LYMPHOCYTES; CELL CYCLE CHECKPOINTS; COHORT STUDIES; COLLAGEN; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FIBROBLASTS; HUMANS; IMMUNOTHERAPY; MICE; MUTATION; NEOPLASM METASTASIS; PHENOTYPE; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 85042495633     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature25501     Document Type: Article

References (34)

1. Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567 (2014).
2. Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558-562 (2014).
3. Bellmunt, J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376, 1015-1026 (2017).
4. Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-Arm, multicentre, phase 2 trial. Lancet 387, 1909-1920 (2016).
5. Balar, A. V. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-Arm, multicentre, phase 2 trial. Lancet 389, 67-76 (2017).
6. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
7. Chalmers, Z. R. et al. Analysis of 100, 000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9, 34 (2017).
8. Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189-2199 (2014).
9. Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
10. Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207-211 (2015).
11. Chen, D. S. & Mellman, I. Oncology meets immunology: The cancer-immunity cycle. Immunity 39, 1-10 (2013).
12. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315-322 (2014).
13. Burns, M. B., Temiz, N. A. & Harris, R. S. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat. Genet. 45, 977-983 (2013).
14. Gao, J. et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167, 397-404 (2016).
15. Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819-829 (2016).
16. Ribas, A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 5, 915-919 (2015).
17. Benci, J. L. et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167, 1540-1554 (2016).
18. Lin, R.-L. & Zhao, L.-J. Mechanistic basis and clinical relevance of the role of transforming growth factor-β in cancer. Cancer Biol. Med. 12, 385-393 (2015).
19. Massagui, J. TGFβ in cancer. Cell 134, 215-230 (2008).
20. Calon, A. et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat. Genet. 47, 320-329 (2015).
21. Derynck, R. & Zhang, Y. E. SMAD-dependent and SMAD-independent pathways in TGF-β family signalling. Nature 425, 577-584 (2003).
22. Morikawa, M., Derynck, R. & Miyazono, K. TGF-β and the TGF-β family: context-dependent roles in cell and tissue physiology. Cold Spring Harb. Perspect. Biol. 8, a021873 (2016).
23. Flavell, R. A., Sanjabi, S., Wrzesinski, S. H. & Licona-Limón, P. The polarization of immune cells in the tumour environment by TGFb. Nat. Rev. Immunol. 10, 554-567 (2010).
24. Hegde, P. S., Karanikas, V. & Evers, S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin. Cancer Res. 22, 1865-1874 (2016).
25. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014).
26. Dobson, A. J. & Barnett, A. G. An Introduction to Generalized Linear Models 3rd edn. (Chapman & Hall/CRC, 2008).
27. Sjödahl, G. et al. A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res. 18, 3377-3386 (2012).
28. Sjödahl, G. et al. Toward a molecular pathologic classification of urothelial carcinoma. Am. J. Pathol. 183, 681-691 (2013).
29. R Core Team. R: A Language and Environment for Statistical Computing http://www.r-project.org (R Foundation for Statistical Computing, Vienna, Austria, 2016).
30. Rusinova, I. et al. Interferome v2.0: An updated database of annotated interferon-regulated genes. Nucleic Acids Res. 41, D1040-D1046 (2013).
31. Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic β-catenin signalling prevents anti-Tumour immunity. Nature 523, 231-235 (2015).
32. Damrauer, J. S. et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc. Natl Acad. Sci. USA 111, 3110-3115 (2014).
33. Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35-44 (2016).
34. Hedegaard, J. et al. Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. Cancer Cell 30, 27-42 (2016).